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In English
During the past 12 years the journal TABU has consolidated
its status as a producer and publisher of drug information in
Finland. The mention of the journal in the most recent read-
er survey of several publications and other alternatives as the
most common influencial factor in the choice of prescription
may also be considered an achievement. The survey results
were introduced in the issue 2/2005 of TABU. Reader sur-
veys provide valuable feedback helpful in the development of
the journal.
TABU has a circulation 40,000 copies issued six times a
year with annual costs totalling less than 300,000 Euros.
The price of a single copy delivered to the reader is 1.2
Euros. The distribution effort easily encompasses pharm-
aceutical professionals in all fields. The journal is also deliv-
ered to some interest groups abroad.
The times, needs and publishing techniques are develop-
ing, and TABU wants to move with the times. Practical fea-
tures should be promoted, which is a tough assignment for a
publication originating from the realm of the authorities.
This is where the extensive network of experts of the
National Agency for Medicines is expected to be of help.
The intention is to obtain articles with greater emphasis on
the day-to-day practice relative to NAM’s chosen areas of
focus within the EU: biological and paediatric medicines.
According to reader feedback, the themes mostly
preferred included new drugs, drug interactions and adverse
drug reactions. These themes will therefore not be discontin-
ued, but instead be further developed.
The most visible changes in the contents of TABU will
be seen in the October issue of the journal. Reporting on the
usual details of marketing authorisations and cancellations,
pharmacy and other authorisations will be discontinued and
will in future be published on the website of NAM. The vet-
erinary drugs section will also get its own new and a more
specific feature in the journal. These drugs will in future be
discussed especially from the viewpoint of veterinary drug
control. The changes will contribute to making the contents
of the journal reflect the interests of the readership better.
An electronic published version of TABU is intended to
be improved on the website of NAM. This will make it pos-
sible to integrate the new and interesting topic in the journal
called ‘marketing’ into NAM’s normal communications on
the web. The transformation will take effect at the beginning
of next year.
Information available in the media, scientific journals,
the Internet and websites is far beyond what anybody is able
to digest. TABU has attained a high status in Finland as a
supplier of information relative to drug control and objective
data. The reliability of the published information and the
expertise of the authors are also of importance for the
success of the journal in future.
Thank you for your feedback –
TABU will be further developed
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Virpi Tiiro Risto Suominen
M. Sc. (Pharm.) Senior Pharmaceutical Officer
National Agency for Medicines
Dispensaries* in Finland 
The National Agency for Medicines in
collaboration with the Faculty of Phar-
macy of the University of Helsinki has
carried out a study on dispensaries in
Finland in order to survey their present
status and development needs. The
results showed an average dispensary to
be a unit maintained by a municipality
or a joint municipal authority and to
operate in a health care centre. The
authorisation of an average dispensary
has been approved prior to the coming
into force of the Medicines Act. The
manager of a dispensary is usually a
Bachelor of Pharmacy and there is no
other staff. 
There is demand and need for
ward pharmacy in health care. The
staff of dispensaries find ward pharma-
cy interesting and important. Due to
the scarcity of manpower and working
time, the operations are focused on
logistics and the maintenance of the
stocks of medicines.
The history of hospital pharmacy
in its present form in Finland is rela-
tively short compared with e.g. the his-
tory of outpatient pharmacies. In
1934, the Women’s Hospital was the
first among Finnish hospitals to
employ a pharmacist. Prior to 1949,
hospitals purchased their medicines
from private pharmacies. Following the
reform of pharmaceutical legistlations,
hospitals had the right to acquire med-
icines also from pharmaceutical whole-
salers. The legislative reforms and
growing numbers of hospitals increas-
ed the number of pharmaceutical staff
in hospitals. The acquisition, storage,
preparation and distribution of medi-
cines became the normal practice of
hospitals.
Background 
The study material consisted of the
replies received in response to the sur-
vey sent by NAM in 2004 to all
dispensary managers.
In the study special emphasis was
placed on the operations and develop-
mental needs of Finnish dispensaries.
The starting point for the study was,
that if the aim is to develop the public
pharmaceutical services, the present
state of Finnish hospital and health
centre pharmacy should initially be
approached as a whole. It is, for exam-
ple, difficult to develop ward pharma-
cy and multidisciplinary collaboration
until the present state is adequately
known. 
Results 
At the beginning of 2004, there were
183 dispensaries in operation in Fin-
land. The number has decreased rather
significantly in recent years, the num-
ber of dispensaries being 308 in 1990.
The most important reasons for the
decrease in the number of dispensaries
include the mergers of small pharma-
ceutical service units into hospital
pharmacies and the shortage of phar-
macists, with the resultant need to
close down and cease the operation of
dispensaries.
The majority, 156 (85%), of the
dispensaries were municipal. Most of
them operated within primary health
care, i.e. they were linked with health
care centres.
A total of 246 Bachelors and Mas-
ters of Pharmacy were employed in
dispensaries. Of these, 179 were man-
agers of dispensaries and 67 consisted
of other pharmaceutical staff. Other,
non-pharmaceutical, staff at the
dispensaries totalled 149.
In 163 dispensaries (over 89% of
the dispensaries) the manager was a
Bachelor of Pharmacy, 16 dispensaries
were managed by a Master of Pharma-
cy and four were managed by a nurse.
The number of pharmacy staff in addi-
tion to the manager varied in between
zero and four. In most cases the man-
ager of a dispensary worked alone
without other staff.
Fifty-six of the dispensaries (31%)
were, at least to some degree, involved
in the preparation of pharmaceutical
products in 2003. The number of
batches prepared varied from one to
1,445 with the arithmetical mean
being 209 and the median 109. The
preparation of pharmaceuticals requir-
ing an aseptic space was occurring in
22 dispensaries (12%). Only 55% of
these (12) had premises incorporating
a laminar flow cabinet and a changing
room with an airlock for the produc-
tion of pharmaceutical products.
Dispensaries were responsible for
pharmaceutical services incorporating
an average of 192 beds, ranging in
number between 7 and 1,013. The
number of pharmaceutical staff per
one hundred beds was on average 0.7,
i.e. one pharmacist was responsible for
a pharmaceutical service consisting on
average of 139 beds. 
Ward pharmacy and its
development into a multidisciplinary
collaboration were considered as the
most important development needs.
The lack of resources was seen as the
biggest obstacle to development. How-
ever, there is a strong vision among
dispensary managers to move to more
patient-oriented services. The change
requires the recognition of the benefit
of ward pharmacy, courage to break
professional barriers and an improve-
ment in the employment situation. In
addition, more education in the field
of clinical pharmacy is needed.
*) Dispensary means a small hospital
pharmacy unit
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ADR reporting is a rather recent phe-
nomenon: it wasn’t until the beginning
of the 1960s that authorities in Europe
as well as elsewhere, prompted by the
thalidomide catastrophe, started to
search for methods which would
enable the early detection of unexpect-
ed adverse reactions. This is of course
in part impossible, since a rare reaction
will not be detected until the drug is
in wide use, irrespective of how well
the drug is studied before its introduc-
tion. Searching for an international
scapegoat associated with the drugs
called coxibs, for example, is therefore
pointless. It is not a question of the
inadequate safety measures or failed
advance monitoring systems of any
particular company or authority, but
simply of the fact that some rare and
slowly emerging adverse reactions do
not occur until after sufficiently exten-
sive and long-term exposure to the
drug.
The number of ADR reports last
year in Finland amounted to 1,118. It
should be borne in mind, nevertheless,
that one report often contains several
adverse symptoms (and perhaps even
drugs), and therefore the total number
of ADRs is distinctly higher than the
number of reports. 
Adverse reactions of the skin
The most commonly reported
reactions are those of the skin (216 in
all) (figure). They are divided into 
several subcategories, the largest one of
which is epidermal and dermal condi-
tions. This includes a number of ADRs
very different from each other, e.g.
rashes, exacerbation of psoriasis, skin
irritation and photosensitivity. The
total number of reports received was
123. These reports also include effects
of the coxibs (16 in all) and statins (13
in all). This is probably a result of the
frequency of their use. This group also
includes one case of Stevens-Johnson
syndrome exhibited in a celecoxib user,
and this has also been the target of
attention in the assessments and bul-
letins of the FDA and EMEA.
The same main category (skin) of
ADRs above includes urticaria, which
featured in 70 reports. The largest
group of 24 reports consisted of
iodine-containing contrast media, a
group which always attracts a great
number of reports. Other smaller
groups that stick out especially are
hyposensitisation preparations, and
bupropione, and valdecoxib.
Adverse reactions of the
nervous system
The second largest group of reports
was that of the nervous system (177
reactions in all). The group as a cate-
gory is rather heterogeneous, including
e.g. headache, cerebral infarct, convul-
sions or taste disturbances. Attention is
drawn to a couple of points: 59 of
these reports belong to the ATC main
code N, Nervous system. Other groups
consist of statins and coxibs, but the
reactions reported are a mixture, the
likely explanation being their wide use.
Reports on cerebral infarcts or
haemorrhages numbered 14; contra-
ceptive preparations containing
ethinylestradiol were suspected in four
cases, and drugs with an effect on
blood coagulation in three. Cases of
convulsions numbered 11, of which as
many as 7 involved mirtazapine, which
includes a mention of convulsions in
its SPC. Headache was reported associ-
ated with a variety of drugs in 18
reports, and disturbances of the sense
of smell caused by a mixture of drugs
were reported 5 times. Various forms
of lack of sensation were reported in
18 cases, and vertigo was suffered by
16 users of a mixture of drugs. Twelve
reports involved taste disturbances, of
which 7 of those affected were on
terbinafine, of which this reaction is
typical.
‘General’ adverse reactions
The third largest group is a category
defined as general disorders and applica-
tion site conditions, part of the
MedDRA coding system, and contains
a mixture of ADRs. A total of 173
reports were classified as falling into
this group. Reactions associated with
the method of administration (27 in
all) understandably consist of various
rashes, burning sensations and lumps
at the site of injection or e.g. of a med-
icinal plaster, such as those in the three
reports on fentanyl plaster. Fever was
mentioned 46 times and various cases
of oedema were mentioned in 32
reports (oral and pharyngeal oedema
are not included in this category).
Oedema was only reported in the
use of etoricoxib 5 times and celecoxib
3 times. The SPCs of both these drugs
include a mention of this adverse reac-
tion.
Death was reported in 24 cases;
four of the reports stated the adverse
reaction as a contributory factor in the
death, and the rest claimed that it had
caused the death. The cases were iso-
lated, except for three haemorrhaging
ulcers, in two of which the reporting
doctor considered the patient to have
died of the reaction, and in one of
which the adverse reaction was consid-
ered a contributory factor. In all the
cases of ulcer, the medication used was
In English
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a coxib either alone or in combination
with other (anti-inflammatory
analgesic) agents. 
Gastrointestinal and 
hepatic reactions
A total of 118 reports of gastrointesti-
nal adverse reactions were notified.
This group contains quite a mixture of
ADRs. Some type of unspecific symp-
tom was referred to in 70 of the
reports: nausea, abdominal pain, flatu-
lence, vomiting or diarrhoea. Various
contrast media appear in this group
(13 reports), in which nausea is proba-
bly more likely to be associated with
reactions of allergic nature rather than
with gastrointestinal complaints. 
Coxibs also figure in the reports on
gastrointestinal reactions, with 17
reports. The interesting point is that 5
of these reports were about a bleeding
abdominal or duodenal ulcer. The sus-
pected medication in one case was two
different coxibs and acetylsalicylic acid.
According to present knowledge, the
concomitant use of acetylsalicylic acid
and coxibs is indeed detrimental to the
stomach. Seven cases of pancreatitis
were reported, in four of which the
suspected drug was simvastatin. The
only other prominent symptom group
was that of three cases of gingival
hyperplasia, with amlodipine being the
suspected cause.
Adverse reactions of the liver figure
as a main category of their own. The
number of reports received was 35.
Elevations of liver values are recorded
in a different main category, i.e. stud-
ies, which is slightly illogical. There
were 46 cases reported. Statins figure
in the liver complaints (22 times in
total in the above groups), which is
logical as the liver is their target of
effect. A couple of coxibs also appear,
and this may be due to their common
use.
Musculoskeletal disorders
This category included 93 reports. The
biggest group was formed by statins
with 30 reports of muscular pain.
Rosuvastatin stands out in this group
with its 19 reports. Cases or Achilles
tendinitis or associated pain total 19,
all of them concerning fluoroquin-
olones. Fourteen of the cases are typi-
cally associated with levofloxacin. The
MedDRA classification performs an
act here: Achilles tendon ruptures are
recorded in the category of injuries.
There were 11 of them with levoflox-
acin as the suspected culprit. Six
reports concerned back pain, the cause
of which was suspected to have been
verteporfine with the therapeutic indi-
cation of occult subfoveal choroidal
neovascularisation and with back pain
mentioned as a common reaction in its
SPC.
Blood
The number of ADRs associated with
blood were 88, of which 53 concerned
cases of agranulocytosis, granulocyto-
penia or leukopenia. The drug suspect-
ed to have caused the ADRs was most
often clozapine, (19 reports + 1 report
on eosinophilia). In addition to a
group of eight psychiatric drugs, one
that stands out with its 4 reports is sul-
phasalazine.
ADR reports received in 2004 by symptom groups
In English
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Immune system disorders
In practice, all of the reported ADRs
in this group were about various aller-
gic conditions: a combination of only
a couple of annoying symptoms at its
mildest, but a life-threatening anaphy-
laxis at its worst. Various allergic symp-
toms were reported 74 times, the
biggest suspected group of drugs being
iodine-containing contrast media (15)
and a couple of other contrast media
(5). The second largest distinct group
is made up of coxibs (9 cases in total),
probably reflecting the common use
and novelty of the drug. Use of
hyposensitisation drugs have caused
four cases of allergic reactions.
Vascular disorders
Various of these, perhaps more like a
mixture of vascular effects, were
reported in 71 cases, the biggest
groups made up of cases of bruising,
hyper- or hypotension, blushing/con-
gestion, a couple of case of vasculitis
and also 4 cases of thrombophlebitis. It
is very difficult to discern any special
pattern in the group, but milnacipran
stands out with its three reports in the
group of cases of hypertension. The
adverse reaction is mentioned in the
SPC.
Cardiac disorders
Adverse cardiac reactions were reported
50 times. Thirty of them concerned
various cases of arrhythmia, for exam-
ple, either as a symptom on its own, or
together with other cardiac symptoms.
The only group standing out is that of
coxibs, of which there are 5 reports.
Myocardial infarction was the reason
for reporting on three occasions, and
cardiac arrest on two. The two last-
mentioned cases involved anaphylaxis
associated with the administration of a
contrast medium. The reactions overall
of this group, except for arrhythmia,
were often isolated cases. It is certain
also that frequently a background mur-
mur would be detected, since various
palpitations are probably very common
in the population.
Pregnancy
In the case of contraceptives, not only
adverse reactions are monitored but
also pregnancies, and then it is a ques-
tion of lack of efficacy rather than an
adverse reaction. The total number of
pregnancies reported was 44, which is
a small number considering the wide
use of contraceptives. About 200,000
Finnish females use systemic hormonal
contraception. The more recent medic-
inal preparations and administrations
are among those most frequently
reported on. This is perhaps rather a
reflection of the general trend in ADR
reporting: the more recent drugs are
more actively reported on, which is of
course desirable.
Psychiatric symptoms
There were 42 reports on psychiatric
symptoms. It is difficult to detect any
special pattern in the material, the
reports referred, for example, to hallu-
cinations, depression, insomnia, night-
mares and anxiety. Various psychiatric
drugs are prominent among the drugs,
especially bupropione, conspicuous
with its five reports, used on this occa-
sion in patients who are trying to stop
smoking.
Infections
This group contains a batch (40
reports) of mixed but understandable
adverse reactions: the drug has (possi-
bly) caused agranulocytosis followed
by sepsis. There are a couple of cases
concerning clindamycin, the use of
which was found to have been associ-
ated with symptoms caused by
Clostridium difficile, and in a couple of
cases the suspected drug was found to
be immunosuppressive either in topical
or systemic use. In such cases the
adverse reaction was, for example, her-
petic rash or erysipelas.
Other ADRs
Eye disorders (35) were reported on,
including e.g. conjunctivitis, photo-
phobia, and chromatopsia. The only
group standing out here is five cases of
blurred vision/visual disturbances typi-
cal of telithromycin (rare according to
the SPC). Adverse reactions of the ear
were reported on 10 times, with 3
cases of tinnitus and vertigo among
them.
Metabolic ADRs were reported on
25 times. The cases of either hypo- or
hyperglycaemia associated with insulin
are distinguishable in the group, but
also one associated with olanzapine
and quetiapine (hyperglycaemia).
Some cases of hyponatraemia were
reported, and also of hyperkalaemia.
In English
Translation Mervi Moisander
In English
A 34-year-old inspector of motor vehi-
cles came for an appointment in
November 2003. In the event there
were regular, weekly appointments
continuing until the beginning of the
summer 2005. The man was diagnosed
at first as having symptoms of depres-
sion associated with decision making
difficulties, continuous tiredness, diffi-
culties of concentration and night-
mares. The underlying background
comprised a particularly difficult child-
hood and adolescence characterised by
dejection and feelings of worthlessness.
At no stage were there any signs of
psychotic illness apparent in the
patient.
Venlafaxine (Efexor depot) therapy
was introduced at an early stage and
given in doses of up to 150 mg x 1.
When the dose was halved in the
beginning of August 2004 and then
followed by discontinuation of the
medication altogether, the patient
reported a complex of symptoms:
light-headedness, discomfort, vertigo,
sensations resembling electric shock.
The symptoms were difficult to man-
age insofar as the patient wanted to
continue the therapy especially as
symptoms of depression had also start-
ed recurring. It was decided to contin-
ue the therapy at a dose of 150 mg x
1.
The dose was again halved on
10.3.2005. The patient took the last
medication on 11.4.2005, and on
13.4.2005 he started experiencing mild
symptoms similar to those associated
with the previous withdrawal. The
symptoms became worse: the patient
experienced continuous sparks of light,
confusion, vertigo over the whole area
of the head, ocular tenderness inhibit-
ed eye movement, and it felt like hav-
ing electricity in the head. At home he
was unable to carry on with daily
chores, and as a consequence, he was
written off sick for a week.  Sick leave
due to depression had not been neces-
sary earlier because of the high thresh-
old the patient had for taking sick
leave. As late as 2.5 weeks after the dis-
continuation of the therapy the patient
experienced difficult symptoms, the
most severe of which was the feeling of
sparks of light in the head. The symp-
toms have gradually disappeared alto-
gether, the therapy has been discontin-
ued and the patient is back at work.
Own observation of an ADR
Withdrawal symptoms following discontinuation of
venlafaxine therapy
Päivi Meretoja
MD, Lecturer in Neurology, Senior Specialist in Psychotherapy
Tervola Health Centre
Comment 
The adverse reactions of antidepressants with an effect on the serotonin and noradrenaline re-uptake inhibition (SSRI/SNRI)
have in recent times been the focus of special interest. An assessment was made in April 2005 by the CHMP of EMEA of the
safety of use of SSRI/SNRI antidepressants in children and adolescents. 
The United Kingdom’s Medicine and Healthcare Products Regulatory Agency has recently reviewed safety of SSRI/SNRI
products (http://www.mhra.gov.uk/news/2004/SSRIfinal.pdf ). According to the review, withdrawal reactions occur with all
SSRI/SNRIs, most commonly with paroxetine and venlafaxine. According to clinical studies, approximately 30% of patients
will experience withdrawal reactions upon stopping venlafaxine treatment, and of these up to approximately 12% will be
severe in nature. The most commonly reported withdrawal reactions were dizziness, headache, nausea and/or vomiting, sleep
disturbances (including insomnia and abnormal dreams), diarrhoea, agitation, anxiety, sweating, tremor, paraesthesia, palpita-
tions and emotional instability.
The kind of experiences similar to electric shock as described in this case study have seldom been reported as a withdrawal
symptom of venlafaxine. In the database of adverse reactions maintained by NAM this report is the only one of its kind.
Withdrawal symptoms on the whole have seldom been reported. In addition to the case above, a 39-year-old woman experi-
enced upper abdominal pains and feeling of swelling for a week following the withdrawal of venlafaxine therapy. Withdrawal
symptoms in a newborn as a result of mother’s use of venlafaxine during pregnancy have also been reported once.
The SPC for Efexor mentions symptoms caused by withdrawal of therapy and includes instructions for a gradual
withdrawal.
Annikka Kalliokoski
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